<DOC>
	<DOCNO>NCT00672113</DOCNO>
	<brief_summary>This study compare effect Adalat LA Coracten drug level well change blood pressure heart rate feed hypertensive subject . Subjects dose either Adalat Coracten first 2 week , follow drug 2 week , switch back original drug one day . Blood sample , blood pressure , heart rate take treatment period .</brief_summary>
	<brief_title>Effects Adalat LA Coracten Drug Levels , Blood Pressure , Heart Rate Fed Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Mild moderate hypertension ( sit DBP &gt; 95 &lt; 114 mmHg and/or SBP &gt; 140 &lt; 160 mmHg ) currently untreated . Previously diagnose mild moderate hypertension ( DBP 95114 mmHg and/or SBP 140 160 mmHg ) well control current treatment experience adverse event safely switch study treatment . Previously diagnose mild moderate hypertension ( DBP 95114 mmHg and/or SBP 140 160 mmHg ) , well control current treatment , without adverse event , willing participate study . Females pregnant , nurse childbearing age , unless sterilise . Subjects receive form contraception eligible . Subjects medical history cardiac disease within 6 month ( e.g . myocarditis pericarditis , aortic stenosis , myocardial infarction , unstable angina pectoris severe angina pectoris ) . Subjects history evidence congestive heart failure Subjects evidence clinically important arrhythmia conduction disturbance require treatment . Subjects severe liver disease ( liver enzyme twice upper limit `` normal '' ) gastrointestinal ( GI ) tract diseases include inflammatory bowel disease Crohns disease Subjects lactose intolerance . Subjects renal disease ( creatinine &gt; 1.5 mg/dL ) , could alter absorption , metabolism excretion study drug . Subjects Type I diabetes . Subjects take drug may interfere metabolism nifedipine ( cimetidine , ranitidine , quinidine , digoxin , rifampicin , diltiazem , cisapride , quinupristin/dalfopristin , cyclosporin , phenytoin antiepileptic drug , ) . Subjects suffer secondary malignant hypertension . Subjects know contraindication ( e.g . hypersensitivity ) nifedipine calcium channel blocker dihydropyridine class . Subjects previously know clinically significant abnormality laboratory test might suggest investigation . Subjects rest heart rate &lt; 50 bpm &gt; 100 bpm . Subjects history drug and/or alcohol abuse . Subjects unwilling comply protocol . Subjects participate another clinical trial within last month . Subjects neurologic psychiatric illness require medication ( e.g . tricyclic antidepressant , MAO inhibitor ) . Subjects clinical evidence ongoing recent ( within last year ) stroke transient ischemic attack . Subjects preexist severe gastrointestinal oesophageal constriction narrowing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>